Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045279 · ClinicalTrials.gov registry record · Phase 2
PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00045279: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00045279 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045279, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: PEG-interferon alfa-2b may stop the growth of kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have metastatic kidney cancer.
Interventions
- BIOLOGICAL PEG-interferon alfa-2b
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
What the finished NCT00045279 record still lists
NCT00045279 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which PEG-interferon alfa-2b is the first listed.
NCT00045279 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00045279 about?
NCT00045279 is a clinical study titled "PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer". RATIONALE: PEG-interferon alfa-2b may stop the growth of kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have metastatic kidney cancer.
What is the current status of trial NCT00045279?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-04. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00045279?
The interventions under investigation include: PEG-interferon alfa-2b (BIOLOGICAL).
Who is sponsoring clinical trial NCT00045279?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia